Skip navigation

Immodulon Therapeutics

Telephone: 020 3137 6346

Immodulon is a biopharmaceutical company exploring the immunomodulatory properties of naturally occurring saprophytic mycobacteria in a range of important human diseases. Using proprietary knowledge for ‘immunological profiling’, Immodulon has been able to select the relatively small number of organisms that have the required balance of activities to bring about the desired modulation of the immune response. The company's principal therapeutic focus is cancer where it is investigating adjunctive use of mycobacterial immunotherapy with certain existing agents. Clinical trials in advanced pancreatic cancer (+/-gemcitabine), advanced colorectal cancer in conjunction with targeted radiotherapy and melanoma are underway with encouraging preliminary results.